Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Hull

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
Carcinogenesis|June 21, 2013
Reduced type II interleukin-4 receptor signalling drives initiation, but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human case-control epidemiological observationsNicola Ingram, Emma L Northwood, Sarah L Perry, et al.
International Journal of Cancer|October 19, 2023
The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E<sub>2</sub> synthesis and platelet activation in participants of the seAFOod polyp prevention trialGe Sun, Harriett Fuller, Hayley Fenton, et al.
BMJ Open|March 31, 2022
REducing Colonoscopies in patients without significant bowEl DiseasE: the RECEDE Study - protocol for a prospective diagnostic accuracy studyChristopher Bradley, Siew Wan Hee, Lazaros Andronis, et al.
British Journal of Cancer|May 25, 2016
Are there biological differences between screen-detected and interval colorectal cancers in the English Bowel Cancer Screening Programme?Elizabeth Walsh, Colin J Rees, Michael Gill, et al.
The American Journal of Gastroenterology|November 3, 2022
Inflammatory Bowel Disease-Associated Colorectal Cancer Epidemiology and Outcomes: An English Population-Based StudyRebecca J Birch, Nicholas Burr, Venkataraman Subramanian, et al.
Digestion|April 28, 2012
Aspirin users attending for NHS bowel cancer screening have less colorectal neoplasia: chemoprevention or false-positive faecal occult blood testing?Thomas J W Lee, Mark A Hull, Praveen T Rajasekhar, et al.
Cancer Chemotherapy and Pharmacology|November 17, 2020
Correction to: Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega‑3 polyunsaturated fatty acid eicosapentaenoic acidMilene Volpato, Nicola Ingram, Sarah L Perry, et al.
The Journal of Nutrition|May 26, 2021
Luminal Bioavailability of Orally Administered ω-3 PUFAs in the Distal Small Intestine, and Associated Changes to the Ileal Microbiome, in Humans with a Temporary IleostomyGael Nana, Suparna Mitra, Henry Watson, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|June 1, 2024
APOE genotype, eicosapentaenoic acid (EPA) supplementation and n-3 highly unsaturated fatty acid (HUFA) levels in patients with multiple colorectal polyps: A secondary analysis of the seAFOod polyp prevention trialGe Sun, John R Davies, Tracey Mell, et al.
Cancer Chemotherapy and Pharmacology|October 11, 2020
Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acidMilene Volpato, Nicola Ingram, Sarah L Perry, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Carcinogenesis|June 21, 2013
Reduced type II interleukin-4 receptor signalling drives initiation, but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human case-control epidemiological observationsNicola Ingram, Emma L Northwood, Sarah L Perry, et al.
International Journal of Cancer|October 19, 2023
The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E<sub>2</sub> synthesis and platelet activation in participants of the seAFOod polyp prevention trialGe Sun, Harriett Fuller, Hayley Fenton, et al.
BMJ Open|March 31, 2022
REducing Colonoscopies in patients without significant bowEl DiseasE: the RECEDE Study - protocol for a prospective diagnostic accuracy studyChristopher Bradley, Siew Wan Hee, Lazaros Andronis, et al.
British Journal of Cancer|May 25, 2016
Are there biological differences between screen-detected and interval colorectal cancers in the English Bowel Cancer Screening Programme?Elizabeth Walsh, Colin J Rees, Michael Gill, et al.
The American Journal of Gastroenterology|November 3, 2022
Inflammatory Bowel Disease-Associated Colorectal Cancer Epidemiology and Outcomes: An English Population-Based StudyRebecca J Birch, Nicholas Burr, Venkataraman Subramanian, et al.
Digestion|April 28, 2012
Aspirin users attending for NHS bowel cancer screening have less colorectal neoplasia: chemoprevention or false-positive faecal occult blood testing?Thomas J W Lee, Mark A Hull, Praveen T Rajasekhar, et al.
Cancer Chemotherapy and Pharmacology|November 17, 2020
Correction to: Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega‑3 polyunsaturated fatty acid eicosapentaenoic acidMilene Volpato, Nicola Ingram, Sarah L Perry, et al.
The Journal of Nutrition|May 26, 2021
Luminal Bioavailability of Orally Administered ω-3 PUFAs in the Distal Small Intestine, and Associated Changes to the Ileal Microbiome, in Humans with a Temporary IleostomyGael Nana, Suparna Mitra, Henry Watson, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|June 1, 2024
APOE genotype, eicosapentaenoic acid (EPA) supplementation and n-3 highly unsaturated fatty acid (HUFA) levels in patients with multiple colorectal polyps: A secondary analysis of the seAFOod polyp prevention trialGe Sun, John R Davies, Tracey Mell, et al.
Cancer Chemotherapy and Pharmacology|October 11, 2020
Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acidMilene Volpato, Nicola Ingram, Sarah L Perry, et al.
Pageof 9